Alar Pharmaceuticals Inc Ordinary Shares 6785
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 275.50
- Day Range
- TWD 265.00–279.00
- 52-Week Range
- TWD 116.00–465.00
- Bid/Ask
- TWD 266.50 / TWD 267.50
- Market Cap
- TWD 15.22 Bil
- Volume/Avg
- 436,000 / 880,531
Key Statistics
- Price/Earnings (Normalized)
- 40.96
- Price/Sales
- 33.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alar Pharmaceuticals Inc is a drug development company. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 16
- Website
- https://www.alarpharm.com
Comparables
Valuation
|
Metric
|
6785
|
4743
|
NEU
|
|---|---|---|---|
Price/Earnings (Normalized) | 40.96 | — | 15.43 |
Price/Book Value | 17.38 | 5.05 | 12.04 |
Price/Sales | 33.39 | 949.59 | 10.75 |
Price/Cash Flow | 41.64 | — | — |
Price/Earnings
6785
4743
NEU
Financial Strength
|
Metric
|
6785
|
4743
|
NEU
|
|---|---|---|---|
Quick Ratio | 11.98 | 56.54 | 5.68 |
Current Ratio | 12.08 | 58.00 | 5.78 |
Interest Coverage | 5,940.46 | −377.23 | — |
Quick Ratio
6785
4743
NEU
Profitability
|
Metric
|
6785
|
4743
|
NEU
|
|---|---|---|---|
Return on Assets (Normalized) | 54.54% | −10.96% | — |
Return on Equity (Normalized) | 66.26% | −11.75% | — |
Return on Invested Capital (Normalized) | 63.18% | −12.47% | — |
Return on Assets
6785
4743
NEU
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Lhmnvqwrx | Ltwx | $72.4 Bil | |
MKKGY
| Merck KGaA ADR | Fqkjtyxjs | Ybnzpj | $69.1 Bil | |
HLN
| Haleon PLC ADR | Xzgwpblmx | Kbzsx | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Qqrpfvvyp | Ltk | $15.7 Bil | |
VTRS
| Viatris Inc | Mwtyqryjj | Blwy | $13.8 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ymgmmlzkl | Pbg | $12.4 Bil | |
CTLT
| Catalent Inc | Hgxvmxbxb | Zfltld | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Djzlvrnm | Pqwp | $4.5 Bil | |
CURLF
| Curaleaf Holdings Inc | Vzcnkzmhg | Jflk | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Kgbhdfcvc | Ybpdbvs | $3.5 Bil |